Which peptides have been tested in people

Of the 25 compounds, 20 have at least one clinical trial about them in PubMed and 5 have none: BPC-157, IGF-1 LR3, KPV, AOD-9604 and Dihexa. The most tested are Glutathione (481), NAD+ (62) and Kisspeptin-10 (49). Counted again every day from the two registries; nothing here is a claim that a compound works.

CompoundClinical trials about itRandomizedReviewsPapers naming itIn animals onlyRegistered studiesReports to the FDA
Glutathione48126424633,77812,652 (37%)61 (38 done)2,648
NAD+62302810,8993,555 (33%)18 (8 done)51
Kisspeptin-104926153,3461,680 (50%)24 (15 done)1
VIP peptide431912,8041,666 (59%)16 (11 done)30
Thymosin alpha-139277632185 (29%)40 (16 done)251
LL-3717903,041216 (7%)8 (7 done)0
SS-3115140586213 (36%)22 (14 done)3
PT-141151421147 (6%)10 (9 done)1,151
Tesamorelin151421073 (3%)20 (10 done)3,625
DSIP1250407287 (71%)00
Sermorelin950370133 (36%)069
ARA-2905407727 (35%)2 (1 done)0
Semax410210145 (69%)02
MOTS-c33026654 (20%)20
Selank3206849 (72%)00
Ipamorelin2205120 (39%)2 (2 done)13
Epitalon210166103 (62%)00
CJC-1295210365 (14%)15
TB-500110633216 (34%)10 (4 done)5
GHK-Cu11014918 (12%)12
BPC-157001230104 (45%)224
IGF-1 LR300010068 (68%)00
KPV0004513 (29%)00
AOD-9604000233 (13%)00
Dihexa000184 (22%)00

Counted from PubMed (pubmed.ncbi.nlm.nih.gov) and ClinicalTrials.gov (clinicaltrials.gov) on 16 November 2026, and again every day. A clinical trial, randomized trial or review counts when the compound is in its title (for a molecule the body makes, such as NAD+, glutathione or VIP, that includes trials that only measure it); papers are counted by the compound in the title or abstract, or in the title alone for those three; “in animals only” is PubMed's own indexing of a paper as about animals and not people; a registered study counts when its listed interventions name the compound. Reports to the FDA are FAERS reports naming the compound (openFDA): what was reported, never proof of cause and never a rate. Ordered by clinical trials, then randomized trials. Each compound's page lists its newest studies and the exact searches.

The same figures as a file: peptide-research.csv, one row per compound with the exact PubMed searches.

Newest in PubMed

The newest trials and reviews, across compounds

  • Evidence on Glutathione and Boosters for Prevention of Chemotherapy-Induced Neuropathy: A Systematic Review and Network Meta-Analysis

    Glutathione · Systematic review · Basic Clin Pharmacol Toxicol · 1 November 2026 · PMID 42876024

  • Hyaluronic acid-based skin booster with glutathione combined with 1064-nm Nd:YAG laser and oral tranexamic acid for melasma: A prospective comparative study

    Glutathione · Randomized trial · Medicine (Baltimore) · 16 October 2026 · PMID 42888572

  • Human evidence for BPC-157 in orthopaedic and regenerative medicine: a systematic review of efficacy and safety

    BPC-157 · Systematic review · Acta Orthop Belg · 8 October 2026 · PMID 42885452

  • Glutathione in redox homeostasis: Bridging molecular mechanisms, bioavailability constraints, and translational challenges in systemic therapeutics

    Glutathione · Systematic review · Biomed Pharmacother · 1 October 2026 · PMID 42585816

  • Extender-dependent effects of reduced glutathione on post-thaw boar sperm quality: A systematic review and meta-analysis

    Glutathione · Meta-analysis · Anim Reprod Sci · 1 October 2026 · PMID 42413192

  • NAD(+) signaling in Parkinson's disease: molecular mechanisms and therapeutic perspectives

    NAD+ · Systematic review · Front Neurol · 30 September 2026 · PMID 42877680

  • Domain-specific effects of NAD(+) precursors on fatigue and functional performance: a systematic review and network meta-analysis

    NAD+ · Systematic review · Front Nutr · 8 September 2026 · PMID 42774067

  • Formulation-dependent differences in systemic glutathione availability: Comparative pharmacokinetics of orally dissolving film and tablet formulations in healthy adults

    Glutathione · Randomized trial · Eur J Pharm Biopharm · 1 September 2026 · PMID 42392376

  • Vasoactive intestinal Peptide as a diagnostic or prognostic biomarker in multiple sclerosis: A systematic review

    VIP peptide · Systematic review · Mult Scler Relat Disord · 1 September 2026 · PMID 42447728

  • Neurotransmitter and neuromodulator imbalance in kisspeptin/GnRH regulation in rodent models of polycystic ovary syndrome and its implications for mental health disorders: A systematic review

    Kisspeptin-10 · Systematic review · Behav Brain Res · 5 August 2026 · PMID 42140496

  • Chronic subcutaneous kisspeptin-10 stimulates gonadotropin secretion for 12 days in healthy men

    Kisspeptin-10 · Randomized trial · Eur J Endocrinol · 3 August 2026 · PMID 42549827

  • Integrative functional bioinformatic analysis of NAD(+)-associated protein coding genes in adipose tissue (dys)function - evidence from targeted rodent transcriptomic studies

    NAD+ · Systematic review · Front Endocrinol (Lausanne) · 21 July 2026 · PMID 42553099

  • Association between blood nicotinamide adenine dinucleotide levels and blood laboratory parameters at baseline and after nicotinamide mononucleotide supplementation in middle-aged healthy individuals: post hoc analysis of a randomized, double-blinded, placebo-controlled clinical trial

    NAD+ · Randomized trial · Geroscience · 1 June 2026 · PMID 41162813

  • NAD+ augmentation by nicotinamide riboside engages SLIT2/ROBO1 signaling to attenuate Th17 inflammation in psoriasis

    NAD+ · Randomized trial · JCI Insight · 28 April 2026 · PMID 42048163

  • Serum kisspeptin levels in women with polycystic ovary syndrome: A systematic review and meta-analysis

    Kisspeptin-10 · Meta-analysis · Med J Malaysia · 1 March 2026 · PMID 41914593

  • Neoadjuvant immunochemotherapy plus thymalfasin in locally advanced gastric cancer: a prospective clinical trial

    Thymosin alpha-1 · Clinical trial · BMC Med · 26 February 2026 · PMID 41749205

  • Intravenous kisspeptin 112-121 bolus does not acutely impact circulating vasopressin in humans

    Kisspeptin-10 · Clinical trial · J Neuroendocrinol · 1 January 2026 · PMID 41273106

  • Associations between kisspeptin hormone level and its genetic polymorphisms with polycystic ovary syndrome

    Kisspeptin-10 · Meta-analysis · Int J Gynaecol Obstet · 1 January 2026 · PMID 40704698

  • Efficacy and Safety of Tesamorelin in People Living With HIV (PLWH) With Lipodystrophy: A Systematic Review and Meta-Analysis

    Tesamorelin · Meta-analysis · J Int Assoc Provid AIDS Care · 1 January 2026 · PMID 42538058

  • Body composition, hepatic fat, metabolic, and safety outcomes of Tesamorelin, a GHRH analogue, in HIV-associated lipodystrophy: A meta-analysis of randomized controlled trials

    Tesamorelin · Meta-analysis · Obes Res Clin Pract · 1 January 2026 · PMID 41545261

Newest in ClinicalTrials.gov

Registered studies updated most recently

  • A Clinical Trial to Assess the Absorption, Safety, and Efficacy of an Oral Nicotinamide Adenine Dinucleotide (NAD+) Supplement in Healthy Adults

    NAD+ · NCT07692633 · recruiting · 80 people · updated 13 November 2026

  • TB-500 (Thymosin Beta 4 17-23 Fragment) for Cardiovascular Biomarkers in Stable ASCVD

    TB-500 · NCT07487363 · recruiting · Phase 1, Phase 2 · 80 people · updated 12 November 2026

  • Tesamorelin for Reduction of Liver Fat in Adults With Fatty Liver Disease

    Tesamorelin · NCT07481734 · recruiting · Phase 2 · 120 people · updated 12 November 2026

  • Study to Evaluate Pharmacokinetics, Safety, and Tolerability of Subcutaneous Injections of Elamipretide in Pediatric Subjects With Barth Syndrome

    SS-31 · NCT07927972 · not yet recruiting · Phase 1 · 6 people · updated 10 November 2026

  • Clinical Trial in Patients With Barth Syndrome- 4TAZPower

    SS-31 · NCT07531251 · recruiting · Phase 4 · 48 people · updated 9 November 2026

  • Tesamorelin to Improve Functional Outcomes After Peripheral Nerve Injury

    Tesamorelin · NCT03150511 · recruiting · Phase 2 · 36 people · updated 9 November 2026

  • Thymosin Alpha 1 and IgM Levels in Sepsis

    Thymosin alpha-1 · NCT07922954 · active, not recruiting · Phase 4 · 36 people · updated 6 November 2026

  • Evaluation of 25(OH)D3 and LL-37 Levels in Periimplant Sulcus Fluid

    LL-37 · NCT07280754 · recruiting · 72 people · updated 3 November 2026

  • Combination Gerotherapeutic Interventions for Healthspan Improvement

    NAD+ · NCT07475546 · completed · Phase 3 · 26 people · updated 30 October 2026

  • An Intermediate Size Expanded Access Protocol of Elamipretide

    SS-31 · NCT04689360 · expanded access available · updated 27 October 2026

  • Thymalfasin Combined With Chemotherapy and Immunotherapy in TNBC Neoadjuvant Treatment

    Thymosin alpha-1 · NCT07884201 · not yet recruiting · Phase 2 · 572 people · updated 20 October 2026

  • Prevent Cardiac Surgery Associated AKI Trial

    Glutathione · NCT06620523 · recruiting · Phase 2 · 242 people · updated 14 October 2026

  • Thymalfasin for Immune Recovery in Adults With Sepsis

    Thymosin alpha-1 · NCT07866118 · recruiting · 60 people · updated 8 October 2026

  • Comparison of Three Qualia NAD⁺ Formulations on Intracellular NAD⁺ Levels

    NAD+ · NCT07132801 · completed · 76 people · updated 6 October 2026

  • Effectiveness of Qualia NAD+ Supplementation on Intracellular NAD Levels

    NAD+ · NCT06505967 · completed · 170 people · updated 5 October 2026

Questions

About the research

Which peptides have been tested in people?

Of the 25 compounds, 20 have at least one clinical trial about them in PubMed and 5 have none: BPC-157, IGF-1 LR3, KPV, AOD-9604 and Dihexa. The most tested are Glutathione (481), NAD+ (62) and Kisspeptin-10 (49).

Which peptides have no clinical trials?

By PubMed's count of clinical trials with the compound in the title: BPC-157 (230 papers, 104 in animals only), IGF-1 LR3 (100 papers, 68 in animals only), KPV (45 papers, 13 in animals only), AOD-9604 (23 papers, 3 in animals only), Dihexa (18 papers, 4 in animals only), counted 16 November 2026.

Does a clinical trial mean a peptide works?

No. A count says how much of the research is in people, not what it found: a trial can be small, early, negative or never published. Each compound's page names its newest trials and reviews so you can read them.

We publish prices and public records; we are not a clinic, a pharmacy or a medical service, and nothing here is advice to take, stop or change any treatment. Compounded peptides and NAD+ are not FDA-approved, and the FDA's position on several of them is changing. A clinician who knows your health is the person to decide whether any of them is right for you.